KLI
APYX icon

Kelman-Lazarov Inc’s Apyx Medical APYX Stock Holding History

Kelman-Lazarov Inc’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,000
Closed -$3.4K – 386
2016
Q2 		$3.4K Hold
2,000
– – ﹤0.01% 316
2016
Q1 		$3K Buy
+2,000
New +$4.03K ﹤0.01% 316

Other funds holding APYX

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kelman-Lazarov Inc's APYX Position: Q3 2016 in Review

Kelman-Lazarov Inc sold out of Apyx Medical (APYX) in Q3 2016, closing a stake of 2,000 shares — an estimated $3.4K sold.

Kelman-Lazarov Inc first reported a position in APYX in Q1 2016 and held it in 2 quarters. The position peaked at $3.4K in Q2 2016. 37 funds tracked by Wall St. Rank hold APYX as of Q3 2016.

  • Kelman-Lazarov Inc reported no remaining Apyx Medical position as of Q3 2016 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 2,000 Apyx Medical shares in Q3 2016, an estimated $3.4K.
  • Kelman-Lazarov Inc first reported a position in Apyx Medical in Q1 2016 and held it in 2 quarters.
  • Kelman-Lazarov Inc's Apyx Medical position peaked at $3.4K in Q2 2016.
  • 37 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2016.

Based on Kelman-Lazarov Inc's 13F filing for Q3 2016, filed 11 Oct 2016.